Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + pegaspargase + anlotinib
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
The LEAP regimen is an investigational combination therapy consisting of the PD-1 checkpoint inhibitor sintilimab, the asparagine-depleting enzyme pegaspargase, and the multi-target tyrosine kinase inhibitor anlotinib. This regimen is specifically being evaluated for the treatment of stage IV extranodal NK/T-cell lymphoma (ENKTL) in patients who are unfit for high-intensity chemotherapy. Sintilimab works by blocking the interaction between PD-1 and its ligands, thereby enhancing the anti-tumor immune response. Pegaspargase, a pegylated form of L-asparaginase, depletes the amino acid L-asparagine, which is essential for the survival of NK/T lymphoma cells that lack asparagine synthetase. Anlotinib provides anti-angiogenic and anti-proliferative effects by inhibiting several receptor tyrosine kinases, including VEGFR, FGFR, PDGFR, and c-Kit.
- Other names
- Sintilimab + Pegaspargase + Anlotinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on sintilimab + pegaspargase + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + pegaspargase + anlotinib.